Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $436,766.40 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total transaction of $436,766.40. Following the sale, the director owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The stock was sold at an average price of $34.00, for a total value of $21,276,622.00.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $35.13 on Friday. The stock has a market capitalization of $25.27 billion, a PE ratio of -58.55 and a beta of 1.11. Roivant Sciences Ltd. has a 1-year low of $10.70 and a 1-year high of $35.90. The business has a 50-day moving average of $30.12 and a 200 day moving average of $27.21.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the company earned ($0.29) EPS. Analysts anticipate that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley raised its holdings in Roivant Sciences by 31.7% in the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the period. Rubric Capital Management LP raised its stake in Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares in the last quarter. State Street Corp raised its stake in Roivant Sciences by 4.8% in the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after buying an additional 911,827 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on ROIV shares. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target on the stock. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Guggenheim increased their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.